KRYS
Krystal Biotech, Inc. · Healthcare · Biotechnology
Momentum-inputs (vergelijkbare managers):
breedte van houders +5.9% ·
aandelenstroom +4.9% ·
netto nieuwe posities 0.0%
· formule
Brede accumulatie: stijgende aandelen bij meer houders
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q3 2025
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 6.57K | $2.18M | n/a | n/a |
| Q2 2026 | 109 | +2 | 18.97M | $7.05B | +12 | −9 |
| Q1 2026 | 109 | 0 | 17.81M | $4.60B | +7 | −8 |
| Q4 2025 | 109 | +2 | 19.84M | $4.89B | +3 | n/a |
| Q3 2025 | 18 | +1 | 16.09M | $2.84B | +2 | −2 |
| Q2 2025 | 15 | -1 | 14.75M | $2.03B | n/a | −1 |
| Q1 2025 | 13 | +1 | 3.64M | $657.03M | +1 | n/a |
| Q4 2024 | 12 | +1 | 3.56M | $557.49M | +1 | n/a |
| Q3 2024 | 10 | +2 | 2.25M | $408.78M | +2 | n/a |
| Q2 2024 | 8 | n/a | 2.10M | $386.05M | n/a | n/a |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 4.34M | +0.1% | $766.40M | 0.0% | ▲ Add | 2 | SEC ↗ ×4 |
| 2 | BlackRock ✦ (passief) | 3.83M | -0.3% | $676.84M | 0.0% | ▼ Trim | 2 | SEC ↗ ×16 |
| 3 | The Vanguard Group ✦ (passief) | 2.79M | -1.1% | $492.91M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 4 | State Street Global Advisors ✦ (passief) | 1.40M | +3.0% | $246.43M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 5 | Capital World Investors ✦ | 809.24K | -14.1% | $142.86M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 6 | Citadel Advisors ✦ | 636.99K | +1743.1% | $112.45M | 0.1% | ▲ Add | 5 | SEC ↗ ×2 |
| 7 | Geode Capital Management ✦ (passief) | 611.24K | -1.3% | $107.92M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 8 | T. Rowe Price ✦ | 467.06K | +78.7% | $82.45M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 9 | Goldman Sachs Group ✦ | 348.25K | n/a | $61.48M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 10 | JPMorgan Chase ✦ | 292.71K | n/a | $51.67M | 0.0% | n/c | 1 | SEC ↗ ×12 |
| 11 | Morgan Stanley ✦ | 234.58K | n/a | $41.41M | 0.0% | n/c | 1 | SEC ↗ ×7 |
| 12 | Millennium Management ✦ | 148.71K | +1083.8% | $26.25M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 13 | Marshall Wace ✦ | 128.96K | +14.8% | $22.77M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 20.13K | +68.2% | $3.55M | 0.0% | ▲ Add | 6 | SEC ↗ ×4 |
| 15 | Wellington Management ✦ | 10.88K | +7.2% | $1.92M | 0.0% | ▲ Add | 6 | SEC ↗ ×4 |
| 16 | Bridgewater Associates ✦ | 9.72K | Nieuw | $1.72M | 0.0% | New | 1 | SEC ↗ |
| 17 | D. E. Shaw & Co. ✦ | 6.81K | -41.9% | $1.20M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 18 | Gotham Asset Management ✦ | 1.31K | Nieuw | $230,725 | 0.0% | New | 1 | SEC ↗ |
"Hun weging" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die manager: de overtuigingsmaatstaf. ✦ = gecureerde manager.
Nieuwe kopers
| Bridgewater Associates | $1.72M | 0.0% |
| Gotham Asset Management | $230,725 | 0.0% |
Verlaten
| Norges Bank | $38.86M | was 0.0% |
| Renaissance Technologies | $12.34M | was 0.0% |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 364 houders, 28.19M aandelen, $7.07B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect het vaakst nog meer bezitten: aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Geen open-market insider-aankopen in ons dekkingsvenster.
Open-market verkopen (S)
Officer, Director, 10% owner · 399 aand · $146,256
Officer, Director, 10% owner · 3.96K aand · $1.42M
Officer, Director, 10% owner · 3.18K aand · $1.14M
Officer, Director, 10% owner · 3.39K aand · $1.22M
Officer, Director, 10% owner · 2.32K aand · $836,281
Officer, Director, 10% owner · 1.24K aand · $449,120
Officer, Director, 10% owner · 1.99K aand · $722,404
Officer, Director, 10% owner · 565 aand · $205,287
Officer, Director, 10% owner · 1.33K aand · $484,390
Officer, Director, 10% owner · 826 aand · $301,832
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie